Psychosocial aspects in phenylketonuria

Related Experiment Video

Updated: Nov 4, 2026

Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures
10:38

Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures

Published on: May 9, 2020

J Weglage1, B Fünders, K Ullrich

  • 1Universitätskinderklinik, Münster, Germany.

European Journal of Pediatrics
|July 1, 1996
PubMed

Insights

Phenylketonuria (PKU) patients treated early showed no increased emotional or behavioral issues at age 10. However, adolescents with PKU experienced restricted social lives and poor disease knowledge, highlighting challenges beyond childhood management.

Area of Science:

  • Metabolic Disorders
  • Developmental Psychology
  • Pediatric Health

Background:

  • Phenylketonuria (PKU) is a rare genetic disorder requiring lifelong dietary management.
  • Psychosocial development in PKU patients is a critical area for long-term well-being.
  • Early intervention and continuous support are crucial for managing PKU.

Purpose of the Study:

  • To assess psychosocial adjustment in children and adolescents with PKU.
  • To compare the emotional and behavioral outcomes of early-treated PKU patients with controls.
  • To investigate the psychosocial situation and disease-specific knowledge in adolescent PKU patients.

Main Methods:

  • Two studies were conducted: a prospective study of 58 10-year-olds and a retrospective study of 34 adolescents (11-18 years).
  • Psychometric instruments included the Personality Questionnaire for Children (PFK 9-14), Mannheimer Biographic Inventory (MBI), and Freiburger Personality Inventory (FPI).
  • Assessments also included self-developed questionnaires on psychosocial status and disease/diet knowledge.

Main Results:

  • Early-treated, normally intelligent 10-year-old PKU patients showed no higher risk for severe emotional/behavioral maladjustment compared to controls.
  • Adolescent PKU patients reported restricted social lives and emotional development.
  • Adolescents exhibited poor knowledge of PKU and its diet, struggling with management without parental support.

Conclusions:

  • While early treatment benefits children with PKU, adolescents face significant psychosocial challenges.
  • The burden of the PKU diet and developmental transitions like puberty can exacerbate emotional and behavioral problems.
  • Improved education and support are needed for adolescents with PKU to enhance disease management and psychosocial well-being.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...